Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SP-8356 in Healthy Volunteers
NCT05574166Phase 1Terminated
- Sponsor
- Shinpoong Pharma
- Start
- Jan 2021
- Primary completion
- Oct 2021
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atherosclerosis and ischemic stroke comparing SP-8356 with Placebo (2 arms). Primary endpoint: Safety and tolerability of single oral doses of SP-8356 up to 3 days. Started Jan 2021; status: terminated.
02
Drugs
SP-8356
03
Conditions
atherosclerosisischemic stroke
Beyond the preview
Go deeper on NCT05574166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574166.